PDF(Pubmed)
Abstract：
Tumor lysis syndrome (TLS) is a potentially fatal oncological emergency that typically develops during the treatment of rapidly proliferating malignancies. It is infrequently reported in solid tumors, such as pulmonary adenocarcinoma. A 59-year-old male patient with shortness of breath presented with a 3.3 cm × 3.0 cm mass in the right upper lobe, along with massive right-sided pleural effusion. A percutaneous needle biopsy was performed, and a diagnosis of pulmonary adenocarcinoma with an epidermal growth factor receptor (EGFR) mutation was made. The patient was treated with afatinib because of the malignant pleural effusion and multiple metastases to the intrathoracic lymph nodes, left scapula, and brain. After 4 days of afatinib treatment, he developed oliguric acute kidney injury and progressively worsening dyspnea. Based on the clinical and laboratory findings, the patient was diagnosed with afatinib-induced TLS. To the best of our knowledge, this is the first reported case of afatinib-induced TLS in pulmonary adenocarcinoma.
摘要：
肿瘤溶解综合征（TLS）是一种可能致命的肿瘤急症，通常在治疗快速增殖的恶性肿瘤期间发展。在实体瘤中很少报道，如肺腺癌。一名59岁的男性患者，呼吸急促，右上叶肿块3.3cm×3.0cm，伴随大量右侧胸腔积液。进行了经皮穿刺活检，并诊断为具有表皮生长因子受体（EGFR）突变的肺腺癌。患者因恶性胸腔积液和胸内淋巴结多发转移而接受阿法替尼治疗，左肩胛骨,和大脑。阿法替尼治疗4天后，患者出现少尿性急性肾损伤，呼吸困难逐渐恶化。根据临床和实验室检查结果,患者被诊断为阿法替尼诱导的TLS.据我们所知,这是在肺腺癌中报道的首例阿法替尼诱导的TLS病例.
